“Our strategic priority this past quarter was to advance our robust clinical programs. To that end, we are pleased that our Phase 1 clinical trial of IMVT-1402 is on schedule to deliver initial data in the coming months, and we look forward to sharing these key first-in-human results with all stakeholders,” said Pete Salzmann, M.D., chief executive officer at Immunovant.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMVT:
- Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023
- Citi opens ‘positive catalyst watch’ on Immunovant into data
- Immunovant price target raised to $33 from $27 at Wells Fargo
- Immunovant price target raised to $34 at Stifel after Argenx data
- Immunovant price target raised to $29 from $27 at H.C. Wainwright